retatrutide mechanism of action triple agonist glp-1 gip glucagon ly3437943 (Triple- Jab): Phase III trial Retatrutide vs. Ozempic: The Triple

2026 regulatory note: Compounded GLP-1 medications are not FDA-approved finished drug products

Growth-hormone-releasing peptides have been flagged in the agency's review of substances used in compounding, and regulators have issued warnings to companies marketing unapproved peptide products for human use

It could take several years and we are beginning the process now, Gordon said

Long-term survival with tumor regression and androgen-induced liver tumors

The most commonly reported side effects are mild to moderate gastrointestinal symptoms such as nausea, constipation, and indigestion, and they usually ease as your body adjusts

Further research should also explore the underlying mechanisms, such as its potential effects on neuroinflammation, mitochondrial function, and amyloid beta/tau pathology, she continued